CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors

por Brenner, Annette K., Reikvam, Håkon, Rye, Kristin Paulsen, Hagen, Karen Marie, Lavecchia, Antonio, Bruserud, Øystein
Publicado 2017

Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular...

por Bruserud, Øystein, Reikvam, Håkon, Fredly, Hanne, Skavland, Jørn, Hagen, Karen-Marie, van Hoang, Tuyen Thy, Brenner, Annette K., Kadi, Amir, Astori, Audrey, Gjertsen, Bjørn Tore, Pendino, Frederic
Publicado 2014

Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells

por Nepstad, Ina, Hatfield, Kimberley Joanne, Grønningsæter, Ida Sofie, Aasebø, Elise, Hernandez-Valladares, Maria, Hagen, Karen Marie, Rye, Kristin Paulsen, Berven, Frode S., Selheim, Frode, Reikvam, Håkon, Bruserud, Øystein
Publicado 2019

Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome

por Kittang, Astrid Olsnes, Kordasti, Shahram, Sand, Kristoffer Evebø, Costantini, Benedetta, Kramer, Anne Marijn, Perezabellan, Pilar, Seidl, Thomas, Rye, Kristin Paulsen, Hagen, Karen Marie, Kulasekararaj, Austin, Bruserud, Øystein, Mufti, Ghulam J.
Publicado 2015

CXXC5 (Retinoid-Inducible Nuclear Factor, RINF) is a Potential Therapeutic Target in High-Risk Human Acute Myeloid Leukemia

por Astori, Audrey, Fredly, Hanne, Aloysius, Thomas Aquinas, Bullinger, Lars, Mas, Véronique Mansat-De, de la Grange, Pierre, Delhommeau, François, Hagen, Karen Marie, Récher, Christian, Dusanter-Fourt, Isabelle, Knappskog, Stian, Lillehaug, Johan Richard, Pendino, Frédéric, Bruserudg, Øystein
Publicado 2013